steven fruchtman  onconova therapeutics inc  zoominfocom spectrum pharmaceuticals appoints steven m fruchtman md an industry veteran as vice president of clinical development nasdaqsppi             share this on delicious digg facebook linkedin twitter what is this « previous release  next release » february   spectrum pharmaceuticals appoints steven m fruchtman md an industry veteran as vice president of clinical development dr fruchtman is a hematologistoncologist with a proven track record in clinical research joins spectrum from allos therapeutics where he led development of folotyn® for hematologic and oncologic indications leading to fda approval of folotyn in relapsed and refractory peripheral tcell lymphoma previously dr fruchtman was at novartis where he was responsible for the development of panobinostat for hematologic and oncologic indications and proleukin for renal cell and melanoma and ortho biotech products a division of johnson  johnson where he led the development of doxil® and others irvine califbusiness wire spectrum pharmaceuticals nasdaqgs sppi a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology today announced the appointment of steven m fruchtman md to the position of vice president of clinical development dr fruchtman will report directly to george tidmarsh md phd the companys chief scientific officer and head of research and development operations and will provide the strategic planning and leadership necessary for managing the companys clinical development of belinostat zevalin® and its other pipeline products we are pleased to announce the appointment of dr fruchtman as our vice president of clinical development said rajesh c shrotriya md chairman chief executive officer and president of spectrum pharmaceuticals steve comes to us from allos therapeutics where he spearheaded the development of folotyn he was instrumental in the presentation of the folotyn data to the odac panel that recommended and ultimately received fda approval in relapsedrefractory peripheral tcell lymphoma he is a board certified hematologist and will be intimately involved with the development of belinostat and zevalin in new indications including large bcell lymphoma i am extremely excited to join spectrum pharmaceuticals spectrum has a very exciting and diversified lineup of drugs both on the market and in latestage clinical development said dr fruchtman belinostat has the potential to be an effective treatment for not only peripheral tcell lymphoma but several other indications as well data from the most recent ash  meeting shows zevalin® provides durable remission rates in patients with bcell lymphomas i am looking forward to bringing these potential life saving treatments to cancer patients as quickly as possible dr fruchtman comes to spectrum from allos therapeutics where he led the development of pralatrexate for hematologic and oncologic indications after a successful academic career at mount sinai hospital and medical school in new york where he was chief of the stem cell transplantation program and prior to joining allos dr fruchtman was senior director of us clinical development and medical affairs for novartis pharmaceuticals at novartis he was responsible for the development of lbh panobinostat for hematologic and oncologic indications and was responsible for registration trials in the united states for cml mm and ctcl lead development of post marketing trials for proleukin il in renal cell and melanoma and lead development of rad afinitor for hematological indications prior to his tenure at novartis he was the medical director of hematology and oncology therapeutics and clinical affairs at ortho biotech products obi lp a division of johnson and johnson pharmaceuticals at obi he was responsible for the clinical development of doxil® phase  trials in hematological malignancies multiple myeloma and nhl velcade and doxil® for nd line multiple myeloma zarnestra® tipifarnib phase  and  trials in mds and aml procrit® for mds and yondelis® trabectedin trials in soft tissue sarcoma and ovarian cancer dr fruchtman has served as an external reviewer for the new england journal of medicine mayo clinic proceedings experimental hematology european journal of hematology leukemia and served on the editorial board of the mount sinai journal of medicine dr fruchtman is an author of more than  lectures presentations books chapters and abstracts dr fruchtman received his bachelor of arts with honors from cornell university and his md from new york medical college about spectrum pharmaceuticals inc spectrum pharmaceuticals is a biotechnology company with fully integrated commercial and drug development operations with a primary focus in oncology the companys strategy is comprised of acquiring developing and commercializing a broad and diverse pipeline of latestage clinical and commercial products the company markets two oncology drugs fusilev and zevalin and has two drugs apaziquone and belinostat in late stage development along with a diversified pipeline of novel drug candidates the company has assembled an integrated inhouse scientific team including clinical development medical research regulatory affairs biostatistics and data management formulation development and has established a commercial infrastructure for the marketing of its drug products the company also leverages the expertise of its worldwide partners to assist in the execution of its strategy for more information please visit the companys website at wwwsppirxcom forwardlooking statement — this press release may contain forwardlooking statements regarding future events and the future performance of spectrum pharmaceuticals that involve risks and uncertainties that could cause actual results to differ materially these statements include but are not limited to statements that relate to our business and its future including certain company milestones spectrums ability to identify acquire develop and commercialize a broad and diverse pipeline of latestage clinical and commercial products leveraging the expertise of partners and employees around the world to assist us in the execution of our strategy and any statements that relate to the intent belief plans or expectations of spectrum or its management or that are not a statement of historical fact risks that could cause actual results to differ include the possibility that our existing and new drug candidates may not prove safe or effective the possibility that our existing and new drug candidates may not receive approval from the fda and other regulatory agencies in a timely manner or at all the possibility that our existing and new drug candidates if approved may not be more effective safer or more cost efficient than competing drugs the possibility that our efforts to acquire or inlicense and develop additional drug candidates may fail our lack of revenues our limited marketing experience our dependence on third parties for clinical trials manufacturing distribution and quality control and other risks that are described in further detail in the companys reports filed with the securities and exchange commission we do not plan to update any such forwardlooking statements and expressly disclaim any duty to update the information contained in this press release except as required by law spectrum pharmaceuticals inc ® zevalin® and fusilev® are registered trademarks of spectrum pharmaceuticals inc redefining cancer care™ and the spectrum pharmaceutical logos are trademarks owned by spectrum pharmaceuticals inc   spectrum pharmaceuticals inc all rights reserved spectrum pharmaceuticals incpaul arndtsenior manager investor relationsx source spectrum pharmaceuticals inc news provided by acquire media close window  back to top delicious digg facebook linkedin twitter copyright  spectrum pharmaceuticals inc onconova therapeutics inc appoints dr steven m fruchtman as chief medical officer employer login post jobs job seeker login sign up search life sciences jobs search job title only radius miles km  news  news by subject  news by disease   news by date  search news get our freeindustry enewsletter email       onconova therapeutics inc ontx appoints dr steven m fruchtman as chief medical officer tweet   am newtown pa jan   globe newswire  onconova therapeutics inc nasdaqontx a clinicalstage biopharmaceutical company focused on discovering and developing novel products to treat cancer today announced the appointment of steven m fruchtman md as chief medical officer and senior vice president research and development dr fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes mds hematologic malignancies and solid tumors he will report to thomas j mckearn md phd the companys president research and development and will provide worldwide strategic planning and leadership for the clinical development and registration of rigosertib and other pipeline product candidates we are pleased to announce the appointment of dr fruchtman as our chief medical officer said ramesh kumar phd president and ceo of onconova steve joins us with extensive experience in managing regulatory interactions with us and european authorities including success in developing innovative oncology products steves broad experience as a practicing hematologistoncologist and his participation in many successful development programs will be invaluable as we design and execute our latestage clinical plans for rigosertib in mds added dr mckearn i am delighted to join onconova therapeutics and to contribute to the latestage clinical development of rigosertib in mds said dr fruchtman rigosertib is a novel ras mimetic which is currently in multiple clinical trials for patients with mds recent data presented at the ash  annual meeting demonstrated the clinical activity of rigosertib as single agent as well as a component of combination therapies i look forward to working with the onconova team to advance these studies dr fruchtman joins onconova after a distinguished career in both academia and the industry most recently he was the chief medical officer of syndax pharmaceuticals where he led the clinical development of entinostat for breast cancer dr fruchtman previously held senior positions at spectrum pharmaceuticals allos therapeutics novartis pharmaceuticals and ortho biotech while at spectrum he was responsible for filing two new drug applications belinostat and apaziquone and oversaw the development of  compounds at allos therapeutics dr fruchtman led the clinical development of pralatrexate folotyn™ culminating in fda approval of this agent in relapsed or refractory peripheral t cell lymphoma prior to joining allos dr fruchtman was senior director of us clinical development and medical affairs for novartis in this role he was responsible for the development of panobinostat for hematologyoncology indications while also leading development of afinitor® for hematologic indications and overseeing post marketing trials for proleukin® in renal cell cancer and melanoma before his tenure at novartis dr fruchtman was the medical director of hematology and oncology therapeutics and clinical affairs at ortho biotech products a division of johnson and johnson pharmaceuticals where he oversaw clinical development for multiple mds programs including zarnestra® tipifarnib in mds and acute myeloid leukemia aml and procrit® in mds during this time he was also responsible for the clinical development of doxil® phase  trials in hematologic malignancies multiple myeloma and nonhodgkins lymphoma velcade® and doxil® for secondline multiple myeloma and yondelis® trabectedin in soft tissue sarcoma and ovarian cancer prior to his time in industry dr fruchtman served as the director of the myeloproliferative disorder program at mt sinai hospital in new york city his commitment to the areas of hematologyoncology and myeloproliferative disorders are exemplified by his service as an external reviewer for the new england journal of medicine mayo clinic proceedings experimental hematology european journal of haematology leukemia and his role as a member of the editorial board of the mount sinai journal of medicine dr fruchtman is an author of more than  lectures presentations books chapters and abstracts he received his bachelor of arts with honors from cornell university and his md from new york medical college about rigosertib rigosertib is a small molecule that inhibits cellular signaling by acting as a ras mimetic this is believed to be mediated by direct binding of rigosertib to the rasbinding domain rbd found in many ras effector proteins including the raf kinases and pik the initial therapeutic focus for rigosertib is myelodysplastic syndromes mds a group of bone marrow disorders characterized by ineffective formation of blood cells that often converts into acute myeloid leukemia aml clinical trials with intravenous iv and oral formulations of rigosertib are being conducted at leading institutions in the us and abroad to date more than  mds patients have been enrolled in clinical trials with rigosertib rigosertib is covered under composition of matter patents issued worldwide orphan designation has been granted for rigosertib in mds in the us europe australia and japan about onconova therapeutics inc onconova therapeutics is a clinicalstage biopharmaceutical company focused on discovering and developing novel products to treat cancer onconovas clinical and preclinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells while causing minimal damage to normal cells in addition to rigosertib the companys most advanced product candidate two other candidates are in clinical stage development and several candidates are in preclinical stages for more information please visit httpwwwonconovacom forward looking statements some of the statements in this release are forwardlooking statements within the meaning of section a of the securities act of  as amended section e of the securities exchange act of  as amended and the private securities litigation reform act of  which involve risks and uncertainties these statements relate to future events or onconova therapeutics incs future operations clinical development of onconovas product candidates and presentation of data with respect thereto regulatory approvals expectations regarding the sufficiency of onconovas cash and other resources to fund operating expenses and capital expenditures onconovas anticipated milestones and future expectations and plans and prospects although onconova believes that the expectations reflected in such forwardlooking statements are reasonable as of the date made expectations may prove to have been materially different from the results expressed or implied by such forwardlooking statements onconova has attempted to identify forwardlooking statements by terminology including believes estimates anticipates expects plans intends may could might will should approximately or other words that convey uncertainty of future events or outcomes these statements are only predictions and involve known and unknown risks uncertainties and other factors including those discussed under the heading risk factors in our most recent annual report on form k and quarterly reports on form q any forwardlooking statements contained in this release speak only as of its date we undertake no obligation to update any forwardlooking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events contact onconova therapeutics benjamin hoffman  bhoffmanonconovaus or media macdougall biomedical communications chris erdman  chrismacbiocomcom help employers find you check out all the jobs and post your resume read at biospacecom related news onconova therapeutics inc ontx to host analyst event in new york city on december   after  billion sale to roche rhhby intermune inc itmn chief jumps to venture capital onconova therapeutics inc ontx announces ontime data presentations at the  american society of hematology annual meeting breaking jp morgan sanofi sanpa says afrezza will be available in  snubs mannkind corporation mnkd ceo retirement news onconova therapeutics inc ontx announces data presentation from combination of rigosertib and azacitidine in mds and nonproliferative aml at the  american society of hematology annual meeting more trouble for retrophin rtrx founder onconova therapeutics inc ontx announces ten presentations at the  american society of hematology annual meeting bungling of virus prompts hiring of cdc safety chief onconova therapeutics inc ontx reports second quarter  financial and operational results salix pharmaceuticals ltd slxp ceo to retire amid inventory pile up drama please enable javascript to view the comments powered by disqus comments powered by disqus • biospacecom • onconova therapeutics inc   • biotechpharma  personnel                 ontx steven m fruchtman insider trades for onconova therapeutics inc bulletin investor alert new york markets after hours market snapshot winners and losers expand keep open close expand keep open close expand keep open close expand keep open close expand keep open close onconova therapeutics inc nasdaq ontx go set alerts find a broker join td ameritrade market index overview profile news charts financials historical quotes analyst estimates options sec filings insiders marketstatecountryus onconova therapeutics inc market closed  quotes are delayed by  min jul    pm ontx quoteszigmancomposite   change   volume volume  quotes are delayed by  min quoteszigmancomposite previous close     change   day low day high    week low  week high   insider activity individual steven m fruchtman dr steven m fruchtman md phd is chief medical officer svpresearch  development at onconova therapeutics inc dr fruchtman was previously employed as chief medical officer by spectrum pharmaceuticals inc chief medical officer by syndax pharmaceuticals inc chiefstem cell transplantation program by icah school of medicine at mount sinai medical directorhermatology  oncology by ortho biotech products lp senior directorus clinical development by novartis pharmaceuticals corp and vice presidentclinical development by allos therapeutics inc he received his undergraduate degree from cornell university an undergraduate degree from new york medical college and a doctorate degree from new york medical college transactions date shares transaction value          derivativenonderivative trans at  per share  copyright  factset research systems inc all rights reserved source factset fundamentals officers and executives dr ramesh kumar president chief executive officer  director mr mark guerin cfo  principal accounting officer dr steven m fruchtman chief medical officer svpresearch  development dr manoj maniar senior vice presidentproduct development mr david m stephon senior vice presidentquality management dr e premkumar reddy director mr michael b hoffman chairman mr jack e stover independent director dr viren mehta independent director mr james j marino independent director dr jerome e groopman independent director dr henry s bienen independent director trending tickers quoteszigmancomposite vuzi quoteszigmancomposite jcp quoteszigmancomposite nugt quoteszigmancomposite jnug quoteszigmancomposite tlt x powered by log in  pm edt july   marketstatecountryus new york after marketstatecountryuk london closed marketstatecountryjp tokyo closed marketstatecountryus   marketstatecountryuk   marketstatecountryjp   view all latest news newslatest preince priebus departs as chief of staff as trump gives job to john kelly pthe perils and pleasures of blocking friends and colleagues on social media pwhat’s really happening with target’s cartwheel app pwall street isn’t ready for a point tumble in the dow industrials pbreakingin a tweet trump names gen kelly his new chief of staff pmattel could get wrecked by weak ‘cars ’ toy sales pthis  number sums up why that foxconn deal is overthetop bad for wisconsin pbreakingtrump tweets hes named a new chief of staff john kelly pwall street isn’t ready for a point tumble in the dow industrials plongdated treasury yields see weekly climb psp  nasdaq finish lower after amazon disappointment dow closes at record pthe highest paid athletes in the world in one chart phow to raise your kids to be frugal but not too frugal pcities to move to if you want to work in tech — not including san francisco pwhat donald trump’s battle of wills with jeff sessions teaches you about a difficult boss pone way you’re paying creditcard fees even if you don’t have a card ptrump russia and sanctions what we know pthis is the worst mistake people make at work pmove over breathalyzers ‘textalyzers’ could be used on drivers’ phones pjared kushner’s unorthodox approach to meetings is a cautionary tale for office workers everywhere loading more headlines dow quoteszigmanrealtime    nasdaq quoteszigmanrealtime    sp  quoteszigmanrealtime    kiosk   the retirementors retirement advice from our industry experts our team of financial professionals can help you plan and save for retirement then live well in it congakioskretirementorshtml    alerts congakioskalertshtml    virtual stock exchange our free stockmarket game • trade your virtual portfolio in real time • talk strategies in group discussions • find or create a game that suits you • use our learning center to improve congakioskgameshtml    location scouts housingmarket insights from our realty pros plus the latest data from realtorcom on  home markets across the us • see our complete real estate site congakioskrealestatehtml    lazy portfolios set it and forget it check out the returns on our  lazy portfolios that are made up of lowcost buyandhold index funds • how to create your own lazy portfolio congakiosklazyportfoliohtml  marketwatchcom site index topics help feedback newsroom roster media archive premium products mobile company info code of conduct corrections advertising media kit advertise locally reprints  licensing broker center your ad choices follow marketwatch rss podcasts wsjcom barrons online bigcharts virtual stock exchange financial news london wsjcom small business realtorcom mansion global copyright   marketwatch inc all rights reserved by using this site you agree to the terms of service privacy policy and cookie policy intraday data provided by six financial information and subject to terms of use historical and current endofday data provided by six financial information all quotes are in local exchange time realtime last sale data for us stock quotes reflect trades reported through nasdaq only intraday data delayed at least  minutes or per exchange requirements marketwatch top stories link to marketwatchs slice  microsoft personalized ad preferences to opt out of personalized ads in this browser your browser history must allow firstparty and thirdparty cookies and you must have your browsing experience set to not delete browsing history on exit instructions for enabling cookies and configuring your browsing history may be available in your browsers settings privacy or help documentation sign in hold on… we’re sorry but this didn’t work you can’t turn off personalized ads right now because your browser is currently blocking thirdparty cookies we can help you fix this issue let’s get started depending on what browser you use open options or settings make sure that thirdparty cookies are not blocked anymore to find out how search your browser’s help revisit httpchoicemicrosoftcomoptout and then on the “personalized ads in this browser” tile click off ext about our ads to create a more customized online experience some of the ads you may receive on microsoft websites and apps are tailored to your previous activities searches and site visits youre in control and heres where you can make the advertising choice thats right for you ext where can i learn more about advertising on microsoft websites and apps microsoft partners with oath appnexus and other third party service providers to help present customized content and display advertisements on msn outlookcom and other websites and apps microsoft also delivers search ads to bing and our search syndication partners learn more about microsoft’s privacy practices here you can learn more about interestbased ads from oath and appnexus in their privacy statements oath and appnexus what choices do i have about interestbased advertising on this page you can opt out of receiving interest based advertising from microsoft you can also opt out of receiving interestbased advertising from all selfregulatory members including microsoft oath appnexus and other third party ad networks at the following sites in the us digital advertising alliance daa in europe european interactive digital advertising alliance edaa in canada ad choices digital advertising alliance of canada daac you can control interestbased advertising in windows apps by turning off the advertising id in windows settings more choices do you want personalized ads from other companies questions if you have a privacy question or a question for the chief privacy officer of microsoft please contact us by using our web form we will respond to questions within  days ext personalized ads in this browser off optout is currently unavailable please try again later control the personalized ads setting for this web browser learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off ext personalized ads wherever i use my microsoft account off sign in to change optout is currently unavailable please try again later control the personalized ads setting that applies when you are signed in on any computer or device with your microsoft account including windows windows phone xbox and other devices learn more if you want microsoft to show ads that might be relevant to you click on to show “generic” ads click off if you choose “generic” ads and use a browser your choice applies to everyone when using that browser as long as you do not clear your cookies ext personalized ads in windows in your windows settings you can turn off personalized ads that appear in apps on this device you’ll still see ads but they won’t be personalized anymore if you have windows  access the charms by touching or moving your pointer to the right edge of the screen click or tap settings and then click or tap change pc settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have windows  click or tap the start button click or tap settings click or tap privacy and then turn off let apps use my advertising id for experiences across apps if you have a windows mobile device go to settings tap on privacy tap on advertising id and then turn off let apps use my advertising id for experiences across apps if you want to turn off personalized ads from microsoft wherever you use your microsoft account including apps on windows windows phone xbox and other devices you can do so by selecting the microsoft account option above ext legal privacy  cookies   microsoft syndax names steven m fruchtman md chief medical officer syndax names steven m fruchtman md chief medical officer oct    et from syndax pharmaceuticals inc waltham mass oct   prnewswire  syndax pharmaceuticals inc today announced the appointment of steven m fruchtman md a hematologistoncologist with extensive experience in early and latestage drug development with biopharmaceutical companies and in clinical practice as chief medical officer dr fruchtman will oversee clinical development programs for entinostat in breast lung and other malignancies this will include the companys work with ecogacrin cancer research group and the division of cancer treatment and diagnosis at the national cancer institute nci on the phase  clinical trial of entinostat in patients with recurrent or metastatic estrogen receptorpositive er breast cancer as we continue preparation for the start of the phase  study steve brings highly relevant clinical development experience to our company said arlene m morris syndaxs chief executive officer his expertise will prove to be beneficial as we continue to evaluate the development of entinostat in other solid and hematological tumors prior to joining syndax dr fruchtman was chief medical officer at spectrum pharmaceuticals inc where he oversaw the development of multiple hematology and oncology products including three marketed drugs fusilev® zevalin® and folotyn® he supervised the preparation of the anticipated new drug application nda filings for belinostat and apaziquone in addition he oversaw clinical development activities for a pipeline of  compounds in varying stages of development prior to joining spectrum dr fruchtman was vice president of clinical research at allos therapeutics inc senior director of us clinical development and medical affairs oncology at novartis pharmaceuticals corporation and medical director of hematology and oncology therapeutics at johnson  johnson pharmaceuticals while at novartis dr fruchtman was a leader in the development of panobinostat a histone deacetylase hdac inhibitor and everolimus an mtor inhibitor for hematological indications dr fruchtman holds a bachelors degree in neurobiology from cornell university and a medical degree from new york medical college he completed an internal medicine residency at suny downstate medical center and specialty training in hematology and oncology at the mount sinai hospital dr fruchtman held faculty positions at mount sinai hospital where over that time he served as director of the myeloproliferative disorder program clinical director of the division of hematology stem cell transplantation service hematology fellowship training program sickle cell program and mount sinai hematology faculty practice associates dr fruchtman is also a member of the new york academy of science the association of the advancement of science the american college of physicians the american society of hematology the transplantation society the society for experimental biology and medicine and the international society for hematotherapy and graft engineering he is board certified in internal medicine and hematology and is a diplomate of the american board of internal medicine he has lectured around the world and is an author of more than  scientific publications books and book chapters about syndax pharmaceuticals syndax is developing entinostat for the treatment of patients with therapyresistant cancers designated a breakthrough therapy by the fda entinostat is designed to prolong the effectiveness of current cancer treatments through an epigenetic mechanism that reverses drug resistance the company holds worldwide rights to entinostat an oral highly selective hdac inhibitor that is expected to be evaluated in combination with exemestane in a pivotal phase  clinical study for the treatment of er metastatic breast cancer corporate contact bob goodenow chief business officer syndax pharmaceuticals   bgoodenowsyndaxcom media contacts david schull or matt middleman md russo partners     davidschullrussopartnersllccom mattmiddlemanrussopartnersllccom source syndax pharmaceuticals inc view table fullscreen view table fullscreen journalists and bloggers the news you need when you need it join pr newswire for journalists to access all of the free services designated to make your job easier in need of subject matter experts for your story submit a free profnet request and find the sources you need learn more feb    et preview leading breast cancer expert george w sledge jr md joins syndax as an independent director sep    et preview syndaxs entinostat receives breakthrough therapy designation from fda for treatment of advanced breast cancer my news release contains wide tables view fullscreen looking to send a news release with pr newswire take advantage of the worlds leading distribution platform sign up to get started request more information have an account log in search searching for your content advanced search steven m fruchtman md  executive bio compensation history and contacts  equilar atlas   log in  sign up x   as featured in steven m fruchtman md chief medical officer and senior vice president research and development at onconova therapeutics inc view full profile are you steven m fruchtman md claim your profile   sign up for equilar atlas and view steven m fruchtman mds full profile with equilar atlas you can identify corporate executives in steven m fruchtman mds network and community follow changes in steven m fruchtman mds employment and moneyinmotion connect with steven m fruchtman md through your network of contacts steven m fruchtman mds executive work history current chief medical officer and senior vice president research and development onconova therapeutics inc past to view steven m fruchtman mds complete executive work history sign up now age      steven m fruchtman mds biography dr fruchtman has served as our chief medical officer and senior vice president research and development since january  dr fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes hematologic malignancies and solid tumors from june  to january  dr fruchtman was a hematology oncology drug development consultant from september  to june  dr fruchtman served as chief medical officer at syndax pharmaceuticals inc a biopharmaceutical company from july  to july  dr fruchtman was the chief medical officer and senior vice president of r  read more dr fruchtman has served as our chief medical officer and senior vice president research and development since january  dr fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes hematologic malignancies and solid tumors from june  to january  dr fruchtman was a hematology oncology drug development consultant from september  to june  dr fruchtman served as chief medical officer at syndax pharmaceuticals inc a biopharmaceutical company from july  to july  dr fruchtman was the chief medical officer and senior vice president of research and regulatory affairs at spectrum pharmaceuticals from february  to june  he was vice president of research at spectrum pharmaceuticals inc a biopharmaceutical company from february  to january  dr fruchtman was vice president clinical research at allos therpeutics inc a biopharmaceutical company prior to this dr fruchtman held senior positions at novartis and ortho biotech products dr fruchtman was on the faculty of the mount sinai school of medicine and was the director of the stem cell transplantation and myeloproliferative disorder programs at mount sinai hospital in new york city dr fruchtman received his medical degree from new york medical college and his ba from cornell university source onconova therapeutics inc on    sign up for equilar atlas and view steven m fruchtman mds full profile by accessing equilar atlas you can view bios network salary and wealth events of industryleading executives like steven m fruchtman md more specifically youll be able to identify corporate executives in steven m fruchtman mds network and community follow changes in steven m fruchtman mds employment and moneyinmotion connect with steven m fruchtman md through your network of conections view full profile   search for over  executive profiles bio example steven m fruchtman md steven m fruchtman mds connections  sign up now to view steven m fruchtman mds  connections » manoj maniar senior vice president product development onconova therapeutics inc jack e stover dir president and chief executive officer interpace diagnostics group inc ajay bansal chief financial officer viewray inc thomas j mckearn board member advaxis ramesh kumar dir president and chief executive officer onconova therapeutics inc anne m vanlent board member ocera therapeutics inc henry s bienen board member onconova therapeutics inc viren mehta former board member onconova therapeutics inc michael b hoffman chairman of the board onconova therapeutics inc e premkumar reddy board member onconova therapeutics inc popular profiles sign up now to view more executive profiles » thomas j lynch executive chairman te connectivity ltd john j kita evp and cfo a o smith carl g annessa evp and coo hornbeck offshore services inc elon r musk ceo and chairman tesla michael c montgomery board member nmi holdings inc × claim your profile coming soon interested in updating your biography and work history were working on making it happen well email you when this feature is available please enter valid email address done thank you for your interest ok browse executive profiles  a  b  c  d  e  f  g  h  i  j  k  l  m  n  o  p  q  r  s  t  u  v  w  x  y  z equilar homepage equilar atlas equilar insight equilar boardedge equilar engage research services knowledge network about us login ï¿½  equilar all rights reserved privacy policy  marshall street redwood city ca   phone    fax   steven m fruchtman  chief medical officer  senior vice president research  development at onconova therapeutics inc news home advertising board and executive moves energy health care hedge funds m  a private equity technology you have    free profiles   left this month    start your free trial ➤ hey we noticed youre a relsci pro subscriber would you like to view the page there view on relsci pro ➤ email linkedin facebook google tweet reddit permalink steven m fruchtman chief medical officer  senior vice president research  development at onconova therapeutics inc overview in the news relationships paths education memberships career history public holdings transactions awards  honors steven m fruchtman chief medical officer  senior vice president research  development at onconova therapeutics inc overview age  born  awards  number of relationships this person is connected to  people in the news see more marketline newswire april   onconova enrolls first patient in phase iii myelodysplastic syndromes study globenewswire march   onconova enrolls first patient in europe for phase  inspire trial of rigosertib in higherrisk myelodysplastic syndromes globenewswire march   onconova announces publication of rigosertib phase  ontime data in lancet oncology philadelphia inquirer january   people in the news pr newswire october   syndax names steven m fruchtman md chief medical officer see full news coverage and complete stories with relsci professional create your news feed see more relationships see details ramesh kumar cofounder at onconova therapeutics inc e premkumar reddy professor  directorcancer therapeutics program at icahn school of medicine at mount sinai ajay bansal chief financial officer  principal accounting officer at viewray inc avi n oler president  secretary at allos therapeutics inc mark guerin chief financial officer  principal accounting officer at onconova therapeutics inc bimal r shah chief financial officer  treasurer at allos therapeutics inc pablo j cagnoni president chief executive officer  director at tizona therapeutics inc michael b hoffman partner at riverstone holdings llc viren mehta founder at kew group inc alan r williamson former vice presidentbasic research  research strategy at merck  co inc see  more listings with relsci professional start my free trial ➤ see  more paths to steven m fruchtman steven m fruchtman you connections via relationship science steven m fruchtman sync your contacts to see how you can connect with steven m fruchtman start my free trial ➤ see more educational background ba honors  cornell university along with its excellent faculty and facilities cornell university boasts a beautiful location in the finger lakes region of central new york the huge hillside campus overlooks lake cayuga and is crisscrossed by deep gorges and bridges cornell is unique among the ivy league universities in that its agricultural program is part of the state school system cornell is well known for its schools of engineering and hotel management its strengths in research and instruction have earned it membership in the association of american universities and cornell can also boast of a chapter of phi beta kappa cornells athletic teams are called the big red doctor of medicine  new york medical college new york medical college is a health sciences university whose purpose is to educate physicians scientists public health specialists and other healthcare professionals and to conduct biomedical and populationbased research memberships member current american association for the advancement of science the american association for the advancement of science provides science related journal program and education services the firm also promotes the responsible use of science in public policy the company was founded in  and is headquartered in washington dc member current the new york academy of sciences the new york academy of sciences is a membership organization with over  members in  countries they include research scientists at universities and industry as well as representatives of business government and policy organizations our board of governors and presidents council include  nobel laureates and other prominent leaders of academia and industry based in new york and around the world member current american society of hematology the american society of hematology s mission is to further the understanding diagnosis treatment and prevention of disorders affecting the blood bone marrow and the immunologic hemostatic and vascular systems by promoting research clinical care education training and advocacy in hematology member current the transplantation society international leadership in the science education ethics and practice of transplantation member current international society of hematotherapy and graft engineering see  more listings with relsci professional start my free trial ➤ see  more career history chief medical officer  senior vice president research  development   current onconova therapeutics inc onconova therapeutics inc is a clinicalstage biopharmaceutical company which engages in the identification and development of oncology therapeutics it focuses on discovering and developing small molecule drug candidates to treat cancer the company was founded by ramesh kumar and e premkumar reddy on december   and is headquartered in newtown pa chief medical officer  senior vice president research  development    syndax pharmaceuticals inc syndax pharmaceuticals inc operates as a clinical stage biopharmaceutical company which engages in the development of cancer therapies it focuses on the development and commercialization of its lead product candidate entinostat an epigenetic therapy for treatmentresistant cancers the company was founded by richard a heyman eckard weber peter ordentlich ronald m evans and michael downes on october   and is headquartered in waltham ma chief medical officer    spectrum pharmaceuticals inc spectrum pharmaceuticals inc engages in the acquisition development and commercialization of pipeline of latestage clinical and commercial products it targets nonhodgkins lymphoma advanced metastatic colorectal cancer acute lymphoblastic leukemia and multiple myeloma it operates through the following brands fusilev folotyn zevalin marqibo beleodaq evomela eoquin and renazorb the company was founded in december  and is headquartered in henderson nv vice presidentclinical development    allos therapeutics inc allos therapeutics inc is a biopharmaceutical company committed to the development and commercialization of innovative anticancer therapeutics it focuses on the development and commercialization folotyn a pralatrexate injection folotyn is a folate analogue metabolic inhibitor designed to accumulate preferentially in cancer cells it targets the inhibition of dihydrofolate reductase or dhfr an enzyme critical in the folate pathway thereby interfering with dna and rna synthesis and triggering cancer cell death allos therapeutics is also developing folotyn in other hematologic malignancies and solid tumors the company was founded on september   and is headquartered in westminster co senior directorus clinical development prior novartis pharmaceuticals corp novartis pharmaceuticals corp develops manufactures and markets prescription drugs it manufactures and markets prescription drugs used to treat a number of diseases and conditions including cardiovascular dermatological central nervous system bone disease cancer organ transplantation psychiatry infectious disease and respiratory the company was founded in  and is headquartered in east hanover nj directorstem cell transplantation prior the mount sinai hospital the mount sinai medical center is a bed tertiarycare teaching facility acclaimed internationally for excellence in clinical care founded in  the mount sinai medical center encompasses the mount sinai hospital and icahn school of medicine at mount sinai us news  world report named mount sinai medical center to its  honor roll of elite hospitals ranking us th among nearly  hospitals nationwide mount sinai also ranked in  out of  specialties and is top ten in three of those geriatrics  gastroenterology  and heart and heart surgery ” additionally kravis children’s hospital at mount sinai received us news and world report  rankings in seven pediatric specialties cancer cardiology  heart surgery diabetes  endocrinology gastroenterology nephrology pulmonology urology medical directorhermatology  oncology prior ortho biotech products lp ortho biotech products lp provides innovative products and services which are designed to enhance the lives of individuals with serious chronic illnesses the companys products include procrit doxil and leustatin ortho biotech products was founded in  and is headquartered in bridgewater nj member of the editorial board prior mount sinai journal of medicine resident in internal medicine prior suny downstate medical center formally known as the state university of new york health science center at brooklyn—but better known to our patients and brooklyn neighbors as suny downstate medical center—we are older than the brooklyn bridge we trace our roots back to  when a school of medicine was founded at the long island college hospital the new college’s faculty revolutionized medical education in this country by bringing the teaching of medicine to the hospital bedside thus rejecting the idea that physicians should be trained exclusively in university lecture halls today suny downstate is one of the nation’s leading urban medical centers suny downstate comprises a college of medicine college of health related professions college of nursing school of graduate studies school of public health and university hospital of brooklyn the quality of our education research and patient care programs was confirmed with the awarding of the nobel prize in medicine to dr robert furchgott a member of our school of graduate studies faculty since  dr furchgott’s identification of nitric oxide as a signalling molecule important in vascular health has revolutionized care for heart stroke impotence and other diseases as the only academic medical center in brooklyn we serve a large population–over  million people–and one that is among the most diverse in the world we are also an engine of opportunity for students interested in pursuing careers in health care many of our students are the first in their families to attend college chiefstem cell transplantation program prior icahn school of medicine at mount sinai the school commits to dramatically advancing the art and science of medical care through an atmosphere of intense collaborative learning social concern and scholarly inquiry public holdings restricted data only for relsci professional users start my free trial ➤ see more transactions details hidden onconova therapeutics inc raised money in a private placement transaction awards  honors professional certification board certification  american board of internal medicine sponsored by american board of internal medicine other affiliations steven m fruchtman is affiliated with onconova therapeutics inc syndax pharmaceuticals inc spectrum pharmaceuticals inc allos therapeutics inc novartis pharmaceuticals corp the mount sinai hospital ortho biotech products lp mount sinai journal of medicine suny downstate medical center icahn school of medicine at mount sinai youve reached your  free profiles limit this month upgrade to relsci pro today to enjoy unlimited article views and much more start my free trial ➤ still not convinced check out our full listing of features here are you a relsci pro subscriber login to relsci pro  ➤ not a pro subscriber log in here to manage your alerts keep me signed in login  ➤ forgot your password i have read the lexisnexis terms  conditions sign me up  ➤ onconova therapeutics appoints dr steven m fruchtman as chief medical officer nasdaqontx english français register sign in onconova therapeutics appoints dr steven m fruchtman as chief medical officer january    et  source onconova therapeutics newtown pa jan   globe newswire  onconova therapeutics inc nasdaqontx a clinicalstage biopharmaceutical company focused on discovering and developing novel products to treat cancer today announced the appointment of steven m fruchtman md as chief medical officer and senior vice president research and development dr fruchtman is a board certified hematologist with extensive industry experience in clinical research for myelodysplastic syndromes mds hematologic malignancies and solid tumors he will report to thomas j mckearn md phd the companys president research and development and will provide worldwide strategic planning and leadership for the clinical development and registration of rigosertib and other pipeline product candidates we are pleased to announce the appointment of dr fruchtman as our chief medical officer said ramesh kumar phd president and ceo of onconova steve joins us with extensive experience in managing regulatory interactions with us and european authorities including success in developing innovative oncology products  steves broad experience as a practicing hematologistoncologist and his participation in many successful development programs will be invaluable as we design and execute our latestage clinical plans for rigosertib in mds added dr mckearn   i am delighted to join onconova therapeutics and to contribute to the latestage clinical development of rigosertib in mds said dr fruchtman rigosertib is a novel ras mimetic which is currently in multiple clinical trials for patients with mds recent data presented at the ash  annual meeting demonstrated the clinical activity of rigosertib as single agent as well as a component of combination therapies i look forward to working with the onconova team to advance these studies dr fruchtman joins onconova after a distinguished career in both academia and the industry most recently he was the chief medical officer of syndax pharmaceuticals where he led the clinical development of entinostat for breast cancer dr fruchtman previously held senior positions at spectrum pharmaceuticals allos therapeutics novartis pharmaceuticals and ortho biotech while at spectrum he was responsible for filing two new drug applications belinostat and apaziquone and oversaw the development of  compounds at allos therapeutics dr fruchtman led the clinical development of pralatrexate folotyn™ culminating in fda approval of this agent in relapsed or refractory peripheral t cell lymphoma prior to joining allos dr fruchtman was senior director of us clinical development and medical affairs for novartis in this role he was responsible for the development of panobinostat for hematologyoncology indications while also leading development of afinitor® for hematologic indications and overseeing post marketing trials for proleukin® in renal cell cancer and melanoma before his tenure at novartis dr fruchtman was the medical director of hematology and oncology therapeutics and clinical affairs at ortho biotech products a division of johnson and johnson pharmaceuticals where he oversaw clinical development for multiple mds programs including zarnestra® tipifarnib in mds and acute myeloid leukemia aml and procrit® in mds during this time he was also responsible for the clinical development of doxil® phase  trials in hematologic malignancies multiple myeloma and nonhodgkins lymphoma velcade® and doxil® for secondline multiple myeloma and yondelis® trabectedin in soft tissue sarcoma and ovarian cancer prior to his time in industry dr fruchtman served as the director of the myeloproliferative disorder program at mt sinai hospital in new york city his commitment to the areas of hematologyoncology and myeloproliferative disorders are exemplified by his service as an external reviewer for the new england journal of medicine mayo clinic proceedings experimental hematology european journal of haematology leukemia and his role as a member of the editorial board of the mount sinai journal of medicine dr fruchtman is an author of more than  lectures presentations books chapters and abstracts he received his bachelor of arts with honors from cornell university and his md from new york medical college about rigosertib rigosertib is a small molecule that inhibits cellular signaling by acting as a ras mimetic this is believed to be mediated by direct binding of rigosertib to the rasbinding domain rbd found in many ras effector proteins including the raf kinases and pik the initial therapeutic focus for rigosertib is myelodysplastic syndromes mds a group of bone marrow disorders characterized by ineffective formation of blood cells that often converts into acute myeloid leukemia aml clinical trials with intravenous iv and oral formulations of rigosertib are being conducted at leading institutions in the us and abroad to date more than  mds patients have been enrolled in clinical trials with rigosertib rigosertib is covered under composition of matter patents issued worldwide orphan designation has been granted for rigosertib in mds in the us europe australia and japan about onconova therapeutics inc onconova therapeutics is a clinicalstage biopharmaceutical company focused on discovering and developing novel products to treat cancer onconovas clinical and preclinical stage drug development candidates are derived from its extensive chemical library and are designed to work against specific cellular pathways that are important in cancer cells while causing minimal damage to normal cells in addition to rigosertib the companys most advanced product candidate two other candidates are in clinical stage development and several candidates are in preclinical stages  for more information please visit httpwwwonconovacom  forward looking statements some of the statements in this release are forwardlooking statements within the meaning of section a of the securities act of  as amended section e of the securities exchange act of  as amended and the private securities litigation reform act of  which involve risks and uncertainties these statements relate to future events or onconova therapeutics incs future operations clinical development of onconovas product candidates and presentation of data with respect thereto regulatory approvals expectations regarding the sufficiency of onconovas cash and other resources to fund operating expenses and capital expenditures onconovas anticipated milestones and future expectations and plans and prospects although onconova believes that the expectations reflected in such forwardlooking statements are reasonable as of the date made expectations may prove to have been materially different from the results expressed or implied by such forwardlooking statements onconova has attempted to identify forwardlooking statements by terminology including believes estimates anticipates expects plans intends may could might will should approximately or other words that convey uncertainty of future events or outcomes these statements are only predictions and involve known and unknown risks uncertainties and other factors including those discussed under the heading risk factors in our most recent annual report on form k and quarterly reports on form q any forwardlooking statements contained in this release speak only as of its date we undertake no obligation to update any forwardlooking statements contained in this release to reflect events or circumstances occurring after its date or to reflect the occurrence of unanticipated events onconova therapeutics benjamin hoffman  or media macdougall biomedical communications chris erdman  related articles other press releases by onconova therapeutics onconova appoints james j marino esq to board of directors july    onconova therapeutics inc to present corporate update at the cantor fitzgerald healthcare conference july    onconova to host myelodysplastic syndromes mds key opinion leader meeting on tuesday june  in new york city june    onconova presents patient selection criteria and intermediate clinical endpoints for rigosertib in higherrisk myelodysplastic syndromes hrmds at eha annual meeting june    onconova presents clinical data on rigosertib in higherrisk myelodysplastic syndromes hrmds at the  asco annual meeting june     other news releases in directors and officers in the last  days profile onconova therapeutics   subscribe via rss  subscribe via atom  javascript newtown pennsylvania united states   httpwwwonconovacom contact data onconova therapeutics benjamin hoffman  or media macdougall biomedical communications chris erdman  contact with a reader account its easy to send email directly to the contact for this release sign up today for your free reader account already have an account log in here tags biotechnology pharmaceuticals management changes newswire distribution network  management home newsroom rss feeds legal contact us about us globenewswire a nasdaq company is one of the worlds largest newswire distribution networks specializing in the delivery of corporate press releases financial disclosures and multimedia content to the media investment community individual investors and the general public contact us corporate headquarters  rosecrans avenue suite  el segundo ca  phone   fax   european headquarters woolgate exchange  basinghall street london ecv ha uk phone     globenewswire inc all rights reserved